Edesa Biotech, Inc.【EDSA】
Market cap
$35.96M
P/E ratio
| Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | Sep 30, 2023 | Sep 30, 2024 | |
| Net loss | -2,843,029 | -5,026,080 | -5,030,648 | -5,038,949 | -6,364,230 | -13,342,350 | 18 | 8 | -6 |
| Depreciation and amortization | 159,521 | 149,565 | 179,322 | - | - | - | - | - | 186,049 |
| Share-based compensation | 267,222 | 259,379 | 115,546 | 154,313 | 598,359 | 3 | 2 | 1 | 537,492 |
| Gain on payable forgiveness | - | - | - | - | - | - | - | - | 14,766 |
| Accounts and other receivable | - | - | - | - | - | - | - | -562,770 | -356,339 |
| Prepaid expenses and other current assets | - | - | - | - | - | - | - | -301,504 | -197,136 |
| Accounts payable and accrued liabilities | 77,018 | -33,403 | -302,731 | 172,451 | 998,903 | -124,724 | 882,843 | -556,270 | 17,590 |
| Net cash used in operating activities | - | - | -4,699,649 | -4,615,505 | -4,986,340 | -13,664,932 | -12,279,302 | -6,636,483 | -5 |
| Proceeds from issuance of common shares and warrants | - | 6 | - | 5 | 4 | - | - | 4 | 729,387 |
| Proceeds from exercise of warrants | 106,777 | 1 | - | 5 | 3 | 2 | - | 770,532 | - |
| Payments for issuance costs of common shares and warrants | - | 332,764 | - | 398,811 | 475,720 | 188,366 | 328,059 | 285,438 | 107,824 |
| Repayment of debt | - | - | - | - | - | - | - | - | 29,532 |
| Net cash provided by financing activities | - | - | - | 9 | 7 | 14 | 12 | 5 | 592,031 |
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | - | - | -25,903 |
| Net change in cash and cash equivalents | - | - | - | - | - | - | -748,340 | -1,729,522 | -4,324,077 |